

主管:
湖南省卫生健康委员会

主办:
湖南省肿瘤医院

学术顾问:
韩锐 霍仕文 马军
梅建明 孙燕(院士)
王忠民 胥彬 杨汉煜
甄永苏(院士) 周宏灏(院士)

编委会主任:
肖亚洲

名誉主编:
任华益

主编:
王静

副主编:
董晓荣 廖前进 刘昭前
欧阳取长 向阳 杨农
杨小平 张会来 周辉

编辑部主任:
李坤艳

编辑:
董珊珊 刘颖
王娟 于静

责任编辑:
李征

出版:
《肿瘤药学》编辑部

国内发行:
湖南省报刊发行局
邮发代号: 42-391

国外发行:
中国国际图书贸易集团有限公司
(北京399信箱, 100048)
代号: BM2809

目录

院士专论

从抗癌新药研发历程认识药物创新研发的艰巨性(二)
..... 刘昌孝 649

肿瘤治疗新策略

肿瘤免疫治疗新靶标PGE₂受体EP4的研究进展
..... 程志远, 贺梦贤, 张耀, 等 657

PDX模型在肺癌靶向治疗中的应用进展
..... 刘敏琪, 谢宜君, 李朵 666

BMI1在肿瘤中的研究进展
..... 张芝榕, 肖迪, 彭美 675

表观遗传修饰在肿瘤代谢重编程中的作用和机制
..... 许雪萌, 崔适文, 张文龙, 等 686

指南·规范·共识

妇科恶性肿瘤紫杉醇化疗所致过敏反应诊治的中国专家共识(2023年版)
..... 中国抗癌协会妇科肿瘤专业委员会,
中国医师协会微无创医学专业委员会妇科肿瘤学组 693

综述

KRAS突变型肺癌作用机制与治疗策略的最新进展
..... 胡晓庆, 张聿达, 陈阳倩, 等 702

贝伐珠单抗应用于恶性胶质瘤的研究进展
..... 沈西宅, 李庆云, 叶盛英 709

基础研究

EP300调控肝癌细胞侵袭迁移的机制
..... 陈攀, 郭文超, 谢威, 等 714

基于网络药理学和实验验证探讨胃复方对胃癌的效应及作用机制
..... 刘丝雨, 李东芳, 何迎春, 等 719

沉默CDK7通过下调YAP表达诱导子宫内膜癌细胞凋亡
..... 杨姣, 李飞浪, 李娜, 等 729

临床研究

基于药物代谢相关基因构建肺癌预后风险预测模型
..... 刘妙秒, 邓豪余, 赵雅洁, 等 735

中国标准连续出版物号:

ISSN 2095-1264
CN 43-1507/R

商标注册证号:

6125707

印刷:

长沙芙蓉印务广告有限公司

邮购:

《肿瘤药学》编辑部(长沙市岳麓区咸嘉湖路582号湖南省肿瘤医院,邮编:410013)

(本刊发行部全年办理补订手续)

电话:

0731-89762609

网址:

<http://www.zgzlyx.com>

中国知网优先数字出版网址:

<http://www.cnki.net>

邮箱:

zgzlyx2011@163.com

微信服务号:

肿瘤药学杂志

定价:

每本30元,全年180元

出版日期:

2023年12月28日

期刊基本参数:

CN 43-1507/R*2011*B*A4*132*
ZH*P*¥30.00*18*2023-12

MET扩增非小细胞肺癌患者的临床病理特征及其对克唑替尼的响应分析

..... 张海艳,黄成成,栗静,等 744

重组人促红素注射液联合罗沙司他对多发性骨髓瘤肾性贫血患者的治疗效果

..... 侯傲,王莉丽,杨蔓玲,等 751

药事管理

抗肿瘤药物职业暴露对PIVAS工作人员的健康危害评估

..... 李琳,金从国,姚宏文,等 759

肿瘤护理

芦荟联合山茶油预防头颈部肿瘤急性放射性皮炎的随机对照试验

..... 戴怡懿,蒋建文,文清美,等 768

病例报道

卡瑞利珠单抗联合阿帕替尼致严重皮肤不良反应1例

..... 戴丽,王凤玲,孟祥云 773

度伐利尤单抗致反应性皮肤毛细血管增生症1例

..... 丁可,凌静,方成,等 777

本刊版权归《肿瘤药学》编辑部所有,如有印刷质量问题请向编辑部申请更换。

Administrative Office:

Health Commission of Hunan Province

Sponsored by:

Hunan Cancer Hospital

Academic Advisor:

HAN Rui, HUO Shiwen, MA Jun,
MEI Jianming, SUN Yan,
WANG Zhongmin, XU Bin, YANG Hanyu,
ZHEN Yongsu, ZHOU Honghao

Chief of Editorial Board:

XIAO Yazhou

Honorary Editor-in-Chief:

REN Huayi

Editor-in-Chief:

WANG Jing

Deputy Editor-in-Chief:

DONG Xiaorong, LIAO Qianjin,
LIU Zhaoqian, OUYANG Quchang,
XIANG Yang, YANG Nong,
YANG Xiaoping, ZHANG Huilai,
ZHOU Hui

Director of Editorial Department:

LI Kunyan

Editor:

DONG Shanshan, LIU Ying,
WANG Juan, YU Jing

Editor in Charge:

LI Zheng

Publication:

Editorial Department of *Anti-tumor
Pharmacy*

Domestic Distributor:

Hunan Bureau for Distribution of
Newspaper and Periodicals
Code No. 42-391

Overseas Distributor:

China International Book Trading
Corporation (P.O. Box 399, Beijing,
100048, China)
Code No. BM2809

CONTENTS

Academician's Monograph

To understand the difficulty of drug innovation and development from the research and development of anti-cancer new drugs (2)
..... LIU Changxiao 649

New Strategies for Cancer Treatment

Research progress of PGE₂ receptor EP4, a new target of cancer immunotherapy
..... CHENG Zhiyuan, HE Mengxian, ZHANG Yao, et al. 657

Application of PDX models in exploration of targeted therapy for lung cancer
..... LIU Minqi, XIE Yijun, LI Duo 666

Research progress of BMI1 in cancer
..... ZHANG Zhirong, XIAO Di, PENG Mei 675

Role and mechanism of epigenetic modifications in metabolic reprogramming of tumors
..... XU Xuemeng, CUI Shiwen, ZHANG Wenlong, et al. 686

Guide · Standard · Consensus

China expert consensus on diagnosis and treatment of hypersensitivity reaction induced by paclitaxel chemotherapy for gynecological malignant tumors (2023 edition)
..... The Chinese Gynecologic Cancer Society (CGCS) of China Anti-Cancer Association, The Gynecologic Oncology Group of Minimally-Invasive and Noninvasive Medicine Committee of the Chinese Medical Doctor Association 693

Review

Recent advances in studies of KRAS mutated lung cancer
..... HU Xiaoqing, ZHANG Yuda, CHEN Yangqian et al. 702

Advances of bevacizumab in the treatment of glioblastoma
..... SHEN Xizhai, LI Qingyun, YE Shengying 709

Basic Research

Mechanism of EP300 regulation of invasion and metastasis of hepatocellular carcinoma cells
..... CHEN Pan, GUO Wenchao, XIE Wei, et al. 714

Experimental verification of the effect and mechanism of Weifufang on gastric cancer based on network pharmacology
..... LIU Siyu, LI Dongfang, HE Yingchun, et al. 719

Silencing CDK7 promotes the apoptosis of endometrial cancer cells by downregulating the expression of YAP
..... YANG Jiao, LI Feilang, LI Na, et al. 729

China Standard Serial Numbering:

ISSN 2095-1264
CN 43-1507/R

Trademark Registration:

6125707

Printing:

Changsha Fuyin Printing and Advertising Co., Ltd.

Post Address:

Editorial Department of *Anti-tumor Pharmacy* (No.582 Xianjiahu Road, Changsha, Hunan, China, 410013)

Tel: 0731-89762609

Website: <http://www.zgzlyx.com>

Online First: <http://www.cnki.net>

E-mail: zgzlyx2011@163.com

WeChat Service Account:

AntiTumorPharmacy

Price: ¥30/Issue, ¥180/Year

Publishing Date:

Dec. 28, 2023

Basic Information of the Journal:

CN 43-1507/R*2011*B*A4*132* ZH*P*
¥30.00*18*2023-12

Clinical Research

Construction of lung cancer prognostic risk prediction model based on drug metabolism-related genes *LIU Miaomiao, DENG Haoyu, ZHAO Yajie, et al.* 735

The clinicopathological characteristics and response to crizotinib of non-small cell lung cancer patients with MET amplification *ZHANG Haiyan, HUANG Chengcheng, LI Jing, et al.* 744

Effect of recombinant human erythropoietin injection combined with roxadustat in patients with multiple myeloma renal anemia *HOU Jing, WANG Lili, YANG Manling, et al.* 751

Pharmacy Administration

Health hazard assessment of occupational exposure to anti-tumor drugs for PIVAS workers *LI Lin, JIN Congguo, YAO Hongwen, et al.* 759

Nursing

Effects of aloe vera combined with camellia oil in preventing acute radiation dermatitis of patients with head and neck cancers *DAI Yixie, JIANG Jianwen, WEN Qingmei, et al.* 768

Case Report

Severe cutaneous adverse reaction caused by camrelizumab combined with apatinib: a case report *DAI Li, WANG Fengling, MENG Xiangyun* 773

Reactive cutaneous capillary endothelial proliferation induced by durvalumab: a case report *DING Ke, LING Jing, FANG Cheng, et al.* 777

• 特别声明 •

本刊作者文责自负,稿件一经采用,该文的复制权、发行权、信息网络传播权、汇编权等相关权利视为自动转让给本刊。本刊有权将上述权利转授给收录本刊的数据库,如作者不同意文章被转录,请来稿时注明,本刊将做适当处理。